Security Clearance and Fingerprinting Guidelines for Illinois Licensure Applicants
April 1, 2026
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Draximage MDP-25
Synonyms :
technetium tc-99m medronate
Class :
Radiopharmaceutical
Brand Name :
Draximage MDP-25
Synonyms :
technetium tc-99m medronate
Class :
Radiopharmaceutical
Dosage forms and strengths
Injection, lyophilized, for solution, powder
medronic acid (20 mg)
The recommended dosage is 10-20 mCi equivalent to (370-740 MBq) administered intravenously
Not indicated
Refer adult dosing
Actions and Spectrum:
Action:
technetium tc-99m medronate, a radiopharmaceutical agent, exhibits its action primarily through its affinity for bone tissue. It is utilized in nuclear medicine imaging procedures to visualize and assess bone metabolism, aiding in diagnosing and monitoring various skeletal disorders. The action involves selectively binding technetium tc-99m medronate to hydroxyapatite crystals within the bone matrix.
Spectrum:
Bone Scintigraphy: technetium tc-99m medronate is widely used to evaluate bone metastases, osteomyelitis, fractures, and other bone-related abnormalities. Its high affinity for areas of bone remodeling allows for detecting subtle changes in bone metabolism.
Assessment of Bone Lesions: The drug facilitates in the distinction of benign and malignant bone lesions, which aids in the staging and monitoring of cancers including osteosarcoma and multiple myeloma.
Frequency not defined
Neuromuscular & skeletal: Weakness
Hypersensitivity: Hypersensitivity reaction
Gastrointestinal: vomiting, Nausea
Dermatologic: urticaria, Pruritus, skin rash
Central nervous system: dizziness, Chills
Cardiovascular: Hypotension
Black Box Warning:
This radiopharmaceutical drug contains radioactive technetium tc-99m, and its use presents significant risks associated with radioactive exposure and tissue irradiation.
Contraindication/Caution:
Hypersensitivity: Patients manifesting hypersensitivity reactions to Technetium tc-99m medronate or any of its constituent components are strictly contraindicated from its usage. This includes individuals with a history of severe allergic responses or anaphylaxis after radiopharmaceutical exposure.
Severe Renal Impairment: The technetium tc-99m medronate administration is contraindicated in severe renal impairment or end-stage renal disease cases, as the compound is primarily excreted through renal pathways. Impaired renal function may lead to prolonged retention of the radiopharmaceutical, resulting in heightened radiation exposure and potential adverse effects.
Pregnancy and Lactation: Due to the potential risk of ionizing radiation to the developing fetus, technetium tc-99m medronate is contraindicated in pregnant individuals. Moreover, breastfeeding mothers are advised against its usage, as the radiopharmaceutical is possible to transfer to breast milk.
Unresolved Acute Skeletal Trauma: In instances where acute skeletal trauma remains unresolved, the application of technetium tc-99m medronate is contraindicated. unhealed fractures or other traumatic skeletal injuries may impede accurate interpretation of imaging results and consequently affect diagnostic efficacy.
Concurrent Use with Other Radiopharmaceuticals: Concurrent administration of technetium tc-99m medronate with other radiopharmaceuticals is contraindicated. The potential for interactions and resultant alterations in imaging outcomes necessitates a cautious approach to combining radiopharmaceutical agents.
Pediatric Population: technetium tc-99m medronate is contraindicated in the pediatric population, specifically in individuals below a certain age as determined by clinical guidelines. The limited data available and potential differences in radiopharmaceutical dynamics necessitate prudence in pediatric usage.
Pregnancy warnings:
Pregnancy category: N/A
Lactation: Excreted into human milk is known
Pregnancy Categories:
Category A: Studies that were well-controlled and met expectations revealed no risk to the fetus in either the first or second trimester.
Category B: There were a lack of studies on pregnant women and no evidence of risk to the fetus in animal experiments.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Pharmacology:
technetium tc-99m medronate, a radiopharmaceutical agent, is employed in nuclear medicine imaging for its ability to localize in bone tissue.
Pharmacodynamics:
technetium tc-99m medronate operates on the principle of selective bone uptake. It behaves as a bone-seeking agent due to its structural resemblance to hydroxyapatite, a key constituent of bone tissue. Upon intravenous administration, tc-99m medronate rapidly enters the systemic circulation and subsequently binds to hydroxyapatite crystals, which are preferentially located in the bone matrix.
Pharmacokinetics:
Absorption
technetium Tc-99m medronate, a radiopharmaceutical agent, is administered intravenously to patients for diagnostic purposes. Upon injection, the compound rapidly enters the bloodstream, achieving systemic circulation within minutes. The absorption process is nearly instantaneous due to the direct intravenous administration, bypassing the need for absorption through the gastrointestinal tract.
Distribution
Following its rapid absorption, technetium tc-99m medronate exhibits a uniform distribution throughout the body, primarily within the extracellular fluid compartment. The compound readily binds to hydroxyapatite crystals within bone tissues, where its preferential uptake occurs. This distribution pattern allows for accurate imaging of skeletal structures, making it a valuable tool in bone scintigraphy procedures.
Metabolism
technetium tc-99m medronate undergoes minimal metabolic transformation in the body. The compound remains largely unchanged as it localizes within bone tissue for imaging purposes. metabolic pathways do not significantly alter its chemical structure, and the radiopharmaceutical retains its diagnostic integrity throughout its presence in the body.
Excretion and Elimination
The excretion of technetium tc-99m medronate primarily occurs through the renal system. The compound is filtered by the kidneys and subsequently eliminated from the body via urine. Renal excretion ensures the efficient removal of the radiopharmaceutical, minimizing its residual presence in the body after the imaging procedure. It is noteworthy that the relatively short half-life of technetium tc-99m (approximately 6 hours) contributes to its prompt elimination from the body, further enhancing patient safety.
Administration:
For intravenous administration, it is recommended to perform imaging within the optimal time frame of 1-4 hours after the administration. Prior to dosing and after it, patients should ensure sufficient hydration.
Patients should also be advised to empty their bladder right before undergoing imaging and at regular intervals for a duration of 4-6 hours after administration. This precaution helps to minimize radiation exposure to the bladder.
Patient information leaflet
Generic Name: technetium tc-99m medronate
Why do we use technetium tc-99m medronate?
Bone Scintigraphy: One of the primary applications of technetium tc-99m medronate is in bone scintigraphy, a diagnostic imaging technique that aids in the visualization of bone metabolism and the detection of various skeletal abnormalities. tc-99m medronate exhibits a strong affinity for hydroxyapatite crystals found in bone tissue, making it an ideal radiopharmaceutical for evaluating skeletal structures. It is particularly valuable in identifying fractures, bone infections, metastatic lesions, and assessing overall bone health.
Osteomyelitis Detection: technetium tc-99m medronate plays a crucial role in the diagnosis of osteomyelitis, an infection of the bone tissue. By selectively accumulating at sites of active bone inflammation and infection, Tc-99m medronate aids healthcare professionals in pinpointing areas of concern, facilitating early detection, and enabling timely intervention. This application contributes significantly to improved patient outcomes by guiding appropriate treatment strategies.
Metastatic Bone Cancer Assessment: In cases of suspected metastatic bone cancer, technetium tc-99m medronate assists in identifying and characterizing malignant bone lesions. The radiopharmaceutical’s affinity for bone tissue allows for accurate localization and quantification of metastatic lesions, aiding in the staging and monitoring of cancer progression. This information is vital for devising tailored therapeutic approaches and assessing treatment efficacy.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
